J&J's Cash Challenge, Gilead's Life After HCV, Pfizer's Pricing Gripe
Executive Summary
Held in Boston, Sept. 7-8, the Wells Fargo Healthcare Conference saw the likes of Gilead Sciences, Johnson and Johnson and Pfizer discuss their strategies for 2017, pipeline highlights and biggest challenges. We pick out five key pointers from industry leaders.
You may also be interested in...
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.
JnJ Not Sweating Remicade Biosimilar Approval
Johnson & Johnson Inc. does not expect a biosimilar rival to its blockbuster tumor necrosis factor (TNF) inhibitor Remicade (infliximab) will launch in the US this year, despite the FDA approval of Celltrion Inc.'s Inflectra (infliximab-dyyb) April 5, and it remains comfortable with the growth outlook for pharmaceuticals.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.